First Allied Advisory Services Inc. decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 40.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,900 shares of the medical research company’s stock after selling 8,040 shares during the period. First Allied Advisory Services Inc.’s holdings in NeoGenomics were worth $156,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in NEO. Quantitative Systematic Strategies LLC purchased a new position in NeoGenomics during the first quarter worth $100,000. Campbell & CO Investment Adviser LLC increased its position in NeoGenomics by 64.3% during the first quarter. Campbell & CO Investment Adviser LLC now owns 17,127 shares of the medical research company’s stock worth $140,000 after buying an additional 6,700 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in NeoGenomics during the first quarter worth $152,000. Wrapmanager Inc. increased its position in NeoGenomics by 36.6% during the first quarter. Wrapmanager Inc. now owns 26,857 shares of the medical research company’s stock worth $219,000 after buying an additional 7,192 shares in the last quarter. Finally, FDx Advisors Inc. increased its position in NeoGenomics by 19.9% during the first quarter. FDx Advisors Inc. now owns 30,644 shares of the medical research company’s stock worth $250,000 after buying an additional 5,091 shares in the last quarter. 81.07% of the stock is owned by institutional investors.

A number of brokerages have recently commented on NEO. ValuEngine raised NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 17th. BTIG Research reaffirmed a “buy” rating and issued a $15.00 price objective on shares of NeoGenomics in a research report on Thursday, June 21st. Stephens reaffirmed a “buy” rating and issued a $15.00 price objective on shares of NeoGenomics in a research report on Tuesday, June 26th. Zacks Investment Research downgraded NeoGenomics from a “hold” rating to a “sell” rating in a research report on Thursday, July 19th. Finally, BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.63.

In other NeoGenomics news, EVP Steven C. Jones sold 2,000 shares of the business’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $13.25, for a total transaction of $26,500.00. Following the completion of the sale, the executive vice president now owns 241,815 shares of the company’s stock, valued at $3,204,048.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Steven C. Jones sold 44,600 shares of the business’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $14.01, for a total value of $624,846.00. Following the sale, the executive vice president now directly owns 241,815 shares of the company’s stock, valued at approximately $3,387,828.15. The disclosure for this sale can be found here. In the last ninety days, insiders sold 513,041 shares of company stock valued at $7,064,707. Company insiders own 12.20% of the company’s stock.

Shares of NASDAQ:NEO opened at $13.79 on Wednesday. The firm has a market capitalization of $1.13 billion, a PE ratio of 229.83 and a beta of 0.59. The company has a quick ratio of 1.59, a current ratio of 1.74 and a debt-to-equity ratio of 0.77. NeoGenomics, Inc. has a 52 week low of $7.08 and a 52 week high of $15.00.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 24th. The medical research company reported $0.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.01. The business had revenue of $67.70 million during the quarter, compared to the consensus estimate of $66.40 million. NeoGenomics had a negative return on equity of 0.36% and a negative net margin of 0.98%. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.04 earnings per share. research analysts anticipate that NeoGenomics, Inc. will post 0.08 earnings per share for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Featured Article: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.